A facile method for synthesis of poly ethylene glycol (PEG)-armed hyperbranched polyoxetanes is presented along with characterization and use in drug delivery. A series of hyperbranched polyoxetanes with multiple PEG arms were synthesized via a one-pot cationic ring-opening polymerization of 3-ethyl-3-hydroxymethyl oxetane (EHMO) and its PEGylated derivative (EPMO), in which the feed mass ratio of EHMO to EPMO was 98:2, 96:4, 74:26, or 17:83. Characterization methods included nuclear magnetic resonance, dynamic light scattering, Fourier transform infrared, differential scanning calorimetry, and scanning electron microscopy. Toxicity of the synthesized polymers to human dermal fibroblasts was evaluated using the MTT assay. Formulation into particles was carried out to encapsulate the anticancer drug camptothecin using the single oilin-water solvent evaporation method. The resulting drug encapsulated particles were evaluated for antitumor activity using HN12 cells.
Introduction
Hyperbranched polymers and dendrimers with defined structures have been the subject of extensive research over the past decade and have drawn attention for pharmaceutical applications owing to their unique architectures and high content of reactive end groups. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Hyperbranched polymers with a wide range of structural characteristics and properties have been synthesized by different polymerization techniques such as polycondensation, 1,2 proton-transfer polymerization, 13, 14 and ring-opening polymerization (ROP). [15] [16] [17] [18] [19] The structural regularity of hyperbranched polymers is not as high as dendrimers, but synthesis is less complicated and more cost-effective for scale-up, thus positioning hyperbranched polymers as a promising class of vehicles for drug delivery. In particular, hyperbranched polyether polyols have inherently desirable characteristics for drug delivery because hydrophobic drugs can be encapsulated in the hydrophobic core while hydroxyls at the periphery can be functionalized for conjugation with biological targets. 6, [20] [21] [22] Poly(3-ethyl-3-(hydroxymethyl) oxetane) (P(EHMO)) is an example of a hyperbranched polyether polyol synthesized by cationic ROP that contains multiple primary hydroxyl groups. [16] [17] [18] [19] PEGylation has been widely implemented to modify hyperbranched polymers, dendrimers, and nanoparticles to render them biocompatible. [23] [24] [25] In addition to the use of branched PEG, 26 a shell of PEG arms on the periphery of hyperbranched P(EHMO) can be generated through polymerization of ethylene oxide initiated by surface-accessible hydroxyl groups. 27 However, this is usually done by postpolymerization chemical modification and requires peripheral functional groups as anchor points. Inadvertently, postpolymerization PEGylation results in a decrease in the number of functional groups available for drug conjugation or additional functionalization. A strategy to integrate PEG so as to make the carrier biocompatible while maintaining a high proportion of peripheral hydroxyl groups for covalent drug loading is desirable. 25 Herein, we report a facile method for synthesis of PEG-armed hyperbranched polyoxetanes via onepot cationic ROP of EHMO monomer and its PEGylated derivative (EPMO macromonomer). The motivation for incorporating PEG into EHMO prior to polymerization was to reduce synthesis steps for making biocompatible branched polymers as well as to use PEGylated monomer to modulate the structure and properties of the resultant hyperbranched polymers. In this new method, the synthesis of the hyperbranched polyoxetane core by ROP of EHMO was followed by addition of EPMO to produce a hyperbranched macromolecular architecture with PEG arms forming the corona. The synthesis method and characterization of the resultant hyperbranched P(EHMO-EPMO) are reported. In addition, hyperbranched P(EHMO-EPMO) was processed into particles for encapsulation of the anticancer drug camptothecin (CPT) using the single oil-in-water (o/w) solvent evaporation method. The sustained release and antitumor activity of CPT-loaded P(EHMO-EPMO) particles were examined.
Materials and method

Materials
EHMO was received as a gift from Perstorp Polyols (Toledo, OH). Methoxy PEG amines (mPEG-NH 2 ) with molecular weights of 550 and 2000 g mol −1 were purchased from Nanocs (New York, NY) and JenKem Technology USA (Allen, TX), respectively. Boron trifluoride diethyl etherate (BF 3 ·O(C 2 H 5 ) 2 ), dichloromethane (DCM), dimethylformamide (DMF), CPT, chloroform, methanol, 4-nitrophenyl chloroformate (NPC), tetrahydrofuran (THF), and triethylamine (TEA) were purchased from Sigma-Aldrich (St. Louis, MO) and used as received.
Synthesis of EPMO macromonomer
EPMO macromonomer was synthesized by coupling mPEG-NH 2 to EHMO via the hydroxymethyl side group following a procedure described previously (Scheme 1). 28 Briefly, EHMO (2.5 mmol) was dissolved in 5 mL of THF followed by addition of TEA (2.5 mmol) and NPC (2.5 mmol). The mixture was stirred for 24 h and then centrifuged to remove triethylammonium chloride. The supernatant was collected and roto-evaporated to remove the solvent. The residue was further reacted with an equimolar amount of mPEG-NH 2 (M n = 550 or 2000 g·mol −1 ) in 5 mL of DMF at room temperature. At 72 h, the resultant EPMO macromonomer was dialyzed against deionized water and freeze-dried. A 60% yield was obtained.
Synthesis of hyperbranched polyoxetanes
Hyperbranched polyoxetanes were synthesized via a one-pot cationic ROP following a previously reported method (Scheme 2). 18 A three-necked round-bottom flask was placed on a heating mantle at 100°C under a nitrogen purge for 30 min. Subsequently, a temperature of 45°C was maintained during the reaction. Upon discontinuation of the nitrogen flow, 15 mL of DCM and BF 3 O(C 2 H 5 ) 2 catalyst were added. Within 5 min, EHMO was added so that the molar ratio of EHMO to BF 3 ·O(C 2 H 5 ) 2 was 2:1. After 48 h, EPMO was added followed by stirring for 24 h. The reaction mixture was quenched with ethanol. The resultant hyperbranched P(EHMO-EPMO) polyol was dried under vacuum at 60°C for 2 days. A series of P(EHMO-EPMO) polymers were synthesized by adjusting the weight ratio of EPMO to EHMO (98:2, 96:4, 74:26, and 17:83) ( Table 1) . EPMO coupled with mPEG 2000 was used for the synthesis of P(EHMO-EPMO)98:2, P(EHMO-EPMO)96:4, and P(EHMO-EPMO)74:26, whereas EPMO coupled with mPEG 550 was used for the synthesis of P(EHMO-EPMO)17:83. The yield of the synthesized polymers ranged between 50% and 66%.
Preparation of drug-loaded particles
The single o/w solvent evaporation method was used to prepare drug-loaded particles based on P(EHMO-EPMO) polymers. 27 CPT, an anticancer drug, was used as a model drug. Drug solutions were prepared by dissolving 10 mg of CPT in 1 mL of chloroform/methanol (0.75 mL/0.25 mL). P(EHMO-EPMO) (10 mg) was dissolved in 3 mL of chloroform/deionized water (1 mL/2 mL). Drug-loaded particles were prepared by combining the drug and polymer solutions. The mixture was kept at room temperature overnight and then dried under vacuum. The dry residue was resuspended in deionized water and subjected to centrifugation at 13,200 r/min for 1 h to remove unencapsulated CPT. The precipitate was dried under vacuum to obtain drug-loaded particles. Particles without drug were also prepared following the same method. The actual amount of CPT encapsulated by the particles was quantified using UV-visible spectrophotometry at 369 nm in chloroform. Encapsulation efficiency (EE) and loading efficiency (LE) were determined according to the following equations: EE = W 1 / W a and LE = W 1 / W b , where W 1 is amount of encapsulated CPT, W a is total amount of CPT used, and W b is total amount of particles used. The measurements were repeated in triplicate.
Structure characterization
Nuclear magnetic resonance spectroscopy. 13 Fourier transform infrared spectroscopy. Fourier transform infrared (FT-IR) spectra of P(EHMO-EPMO) were obtained from solution-cast films on KBr discs using a Nicolet Magna IR 760 spectrometer.
Differential scanning calorimetry. Thermal analysis measurements were carried out in a nitrogen atmosphere using TA-Q Series Q1000 differential scanning calorimetry (DSC) (TA Instruments, New Castle, DE). Samples (5-6 mg) were heated and cooled between −90°C and 120°C at 10°C/ min. Data from the second heating cycle are reported in Table 1 . Dynamic light scattering measurement. A Malvern Zetasizer Nano S (Malvern Instruments, Malvern, UK) was used to determine the molecular weights of the synthesized polymers and particle sizes. Polymer samples were suspended in chloroform and filtered through a 2 µm syringe filter prior to the measurement. Light scattering intensity was recorded, and scatter intensities were plotted as Zimm plots to calculate the mean particle size and size distribution (i.e. polydispersity index with a value between 0 and 1).
Scanning electron microscopy. Scanning electron microscopy (SEM) images were taken under a scanning electron microscope ZESIS EVO50. Polymer samples were dissolved in chloroform. A few drops of the solution were placed on a silicon wafer and dried under vacuum. The sample was then mounted on the stub and sputter coated with gold. Images were taken at ×35,000 magnification.
In vitro drug release studies
Drug-loaded particles were weighed and suspended in 10 mL of phosphate-buffered saline (PBS) pH 7.4 in a capped conical flask. The suspension was maintained at 37°C. At predetermined intervals, 3 mL of supernatant was collected, and UV-visible absorbance measurements at 369 nm were used to quantify the released drug. After each measurement, 3 mL of fresh PBS was added back to the medium to continue the release study. The experiment was repeated in triplicate.
Cytotoxicity assessment
The cytotoxicity of P(EHMO-EPMO) polymers to human dermal fibroblasts was evaluated. Fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere containing 10% CO 2 and 90% air. The cells were incubated with polymers at different final concentrations (10, 50, 100, and 300 µg/mL) for 48 h. The cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, whereas untreated cells were used as control.
In vitro antitumor activity of CPT-loaded in P(EHMO-EPMO) particles
The HN12 cells used to examine the in vitro antitumor activity of particles were derived from a lymph node metastasis in a patient. 29 HN12 cells were cultured in DMEM supplemented with 10% FBS at 37°C in a humidified atmosphere containing 10% CO 2 and 90% air. The viability of HN12 cells incubated with drug-loaded particles based on P(EHMO-EPMO)74:26 at a final concentration of 10 µg/mL for various lengths of time (i.e., 12, 24, 48, and 72 h) was determined using the MTT assay. HN12 cells incubated with blank particles of P(EHMO-EPMO)74:26 at the concentration of 10 µg/mL was also assessed.
Results
Characterization of hyperbranched P(EHMO-EPMO)s
Prior studies have shown that EHMO monomers form branched polymeric structures through cationic ROP using BF 3 O(C 2 H 5 ) 2 catalysis. 17, 18, 27 In this study, we employed a two-step one-pot polymerization process to construct a hyperbranched core of P(EHMO) and a shell of PEG arms from P(EPMO). 13 C-NMR spectroscopy confirmed the synthesis of P(EHMO-EPMO) copolymers and their branched structures. With reference to Scheme 2 for carbon atom designations, in the 13 C-NMR spectrum of P(EHMO-EPMO)98:2 ( Figure 1) , peak a corresponds to -CH 3 in ethyl group, peak b corresponds to -CH 2 -in ethyl group, peak c corresponds to -CH 2 DB is a key parameter determining the properties of hyperbranched polymers. As summarized in Table 1 , DB of P(EHMO-EPMO) increases with increasing EPMO wt% in the reaction. As expected for P(EHMO-EPMO) polymers based on EPMO/mPEG 2000, increasing the amount of EPMO macromonomer results in an increase in molecular weight for copolymers. P(EHMO-EPMO)17:83 has a molecular weight of 7.8 × 10 3 g mol −1 , which is the lowest among the synthesized polymers. The use of EPMO/mPEG 550 partly accounts for this observation.
FT-IR spectroscopy was used for qualitative characterization of functional groups. As shown in Figure 2 , P(EHMO-EPMO) generally displays a strong peak at 2880 cm −1 due to C-H stretching, a peak at 1110 cm −1 due to C-O stretching, and a peak at 1740 cm −1 due to C=O stretching. As the number of C-O bonds increases due to the incorporation of PEG chains, the absorption peak at 1110 cm −1 becomes broader.
DSC was conducted to elucidate thermal behavior of branched P(EHMO-EPMO)s and controls (Tables 1 and Table S1 (Supplementary file available online)). The core P(EHMO) shows an endotherm in the first cycle at 43°C (Figure 3 ). Considering the high density of peripheral hydroxyl groups, the transition is assigned to a T g due to the formation of a hydrogen-bonded glass during solidification from solution. This endotherm may be partly due to volumetric relaxation as on the second heating cycle T g is at 27°C (Figure 4) . Given that the thermal behavior of EHMO was not reported previously, additional studies are warranted to confirm these preliminary results. Substitution of hydroxyl groups in the P(EHMO) core with polymerized EPMO resulted in a decrease of T g for EHMO/EPMO copolymers. Remarkably, only 2 wt% of EPMO (2000 Da) results in the disappearance of the core T g and the appearance of a new T g at −34°C (Figure 4 ). Increasing the wt% of EPMO (2000 Da) to 4% and 26% results in a small melting endotherm at 50°C-55°C during the first heating cycle (Figure 3) . Given that linear mPEG2000-NH 2 (Figure S2 (Supplementary file available online)) has a T m at 52°C, the small melting endotherms for the 4 and 26 wt% compositions may be due to T m for a crystalline phase formed by the EPMO arms. These melting transitions were not observed in the second cycle ( Figure 4 ). Regardless of heating cycle, T g values for 4 and 26 wt% EPMO compositions were −21°C and −25°C, respectively. P(EHMO-EPMO)17:83 has the highest EPMO composition, which was constructed on the basis of mPEG550-NH 2 . Unlike its linear control mPEG550-NH 2 (Figure S3 (Supplementary file available  online) ) that shows a T m at 12°C, P(EHMO-EPMO) 17:83 only has a T g at −55°C. Despite a high EPMO content, the EHMO core apparently inhibits crystallization. The lower T g suggests a higher chain mobility for shorter P(EPMO) arms.
Characterization of drug-loaded P(EHMO-EPMO) particles
P(EHMO-EPMO) and CPT-loaded P(EHMO-EPMO) particles were prepared using the single o/w solvent evaporation method, and their morphology and size were characterized using SEM and dynamic light scattering (DLS), respectively. According to DLS measurements, the diameter of P(EHMO-EPMO) particles ranged from 361 to 1078 nm. SEM images ( Figure 5) show that the particles were mostly spherical before drug encapsulation and became oval after drug encapsulation. Furthermore, the size of the drug-loaded particles was much larger than that of the blank particles. The size increase and shape change are attributed to drug encapsulation as well as a change in event of aggregation of particles in the presence of drug. Drug LE and particle EE were generally high, ranging from 60% to 80% ( Table 2 ). Drug loss during drug loading into particles was due to resuspension of drug-loaded particles in water and subsequent centrifugation, causing removal of released or unencapsulated CPT.
Cytotoxicity of hyperbranched P(EHMO-EPMO)s
The cytotoxicity of hyperbranched P(EHMO-EPMO) polymers to human dermal fibroblasts was examined. The MTT assay results clearly indicate that cytotoxicity is dependent on dose and EPMO composition ( Figure 6 ). Among the range of the doses from 10 to 300 µg/mL, P(EHMO-EPMO)74:26 and P(EHMO-EPMO)17:83 are more cytocompatible than P(EHMO-EPMO)98:2 and P(EHMO-EPMO)96:4. Only 26.7% cells remained viable after being treated with 10 µg/mL P(EHMO-EPMO)98:2 for 48 h, and the cell viability dropped to 4.4% when the concentration of P(EHMO-EPMO)98:2 increased to 300 µg/mL. A marginal increase in percentage of EPMO did not improve the cytocompatibility of the hyperbranched polymer. P(EHMO-EPMO)96:4 displays a similar level of dose-dependent toxicity as compared to P(EHMO-EPMO)98:2. However, the cytocompatibility of P(EHMO-EPMO) was significantly enhanced as the EPMO composition was increased to 26 or 83 wt%. The viability of HN12 cells was 55.1% in the presence of 300 µg/mL P(EHMO-EPMO)17:83. The cells remained viable as high as 86.6% as the concentration of P(EHMO-EPMO)17:83 was reduced to 10 µg/mL The cytocompatibility of P(EHMO-EPMO)74:26 is similar to that of P(EHMO-EPMO)17:83, although it has a lower percentage of EPMO in the branched structure than P(EHMO-EPMO)17:83. Using P(EHMO-EPMO)74:26 as an example (Figure 7) , the cell morphology observed was consistent with the cell viability assay. As the dose of P(EHMO-EPMO)74:26 was increased, more cells were round and detached or lysed, indicating cell viability loss. In general, a cell viability of 80% or higher indicates good cytocompatibility of the tested polymers at dosage levels (10 µg/mL or lower), which could be used for in vivo testing.
Drug release and antitumor effect of CPT following release
CPT has poor aqueous solubility and antitumor activity can be impaired due to hydrolysis and conversion from a therapeutically active lactone form to an inactive carboxylate form. Encapsulating CPT into particles helps increase CPT stability and sustain its antitumor activity. 30, 31 As shown in Figure 8 , the release kinetics of CPT from P(EHMO-EPMO) particles follows a similar pattern regardless of P(EHMO-EPMO) composition. Almost 100% of the encapsulated drug was released over 9 days. An initial burst release of CPT from P(EHMO-EPMO) particles occurred in the first 5 h, followed by a sustained slower release. Since CPT is hydrophobic, a hydrophobic interaction between the drug and the hydrophobic core of P(EHMO-EPMO) is presumed responsible for the sustained drug release. The antitumor effect on HN12 cells, derived from metastatic squamous cell carcinoma, was evaluated for P(EHMO-EPMO)74:26 drug-loaded particles. HN12 cells were cultured in the presence of 10 µg/mL drug-loaded P(EHMO-EPMO)74:26 particles for 12, 24, 48, or 72 h. The cellular enzymatic activity was quantified with the MTT assay. HN12 cells treated with blank P(EHMO-EPMO)74:26 particles under the same condition were also assessed to study the effect of particles alone on the cells. A marked decrease in the cellular activity of HN12 cells was observed as the incubation with drug-loaded particles was extended from 12 to 72 h (Figure 9 ). Cell viability was reduced to 20% by 12 h incubation of drug-loaded particles and further reduced to 1% by 72 h incubation. This study suggests that longer incubation along with sustained release of CPT results in higher toxicity for HN12 cells. In vitro, 50% of the encapsulated CPT was released from P(EHMO-EPMO)74:26 particles in 56 h and complete drug release took over 200 h. Taken together, it is expected that the sustained release beyond 72 h would result in complete cell death. Although the dose of drug-loaded particles remains to be optimized, the above-mentioned studies demonstrate high potency of the encapsulated drug due to sustained release. Interestingly, the cellular activity of HN12 cells was reduced initially, as measured at 12 h post incubation with blank P(EHMO-EPMO)74:26 particles, but recovered following longer incubations. For example, 81% cell viability remained at 72 h post treatment, indicating the adjustment of the cells to the addition of particles and the relatively low toxicity of particles themselves to the cells.
Discussion
Drug delivery carriers are commonly modified with PEG to gain favorable biological compatibility. PEGylation of drug carriers can be accomplished in two ways: directly grafting PEG to the carrier or forming PEG arms through polymerization of ethylene oxide. To efficiently couple PEG to the branched structures and keep the degree of PEGylation as low as possible, we explored a new route to synthesize PEGylated polyether polyols via a two-step cationic ring-opening copolymerization of EHMO and PEGylated EHMO (i.e. EPMO). In our reaction scheme, a hyperbranched polyether P(EHMO) core was formed by ROP of EHMO, driven by the nucleophilic attack of either the oxygen atom in the ring or the hydroxyl group of EHMO. Since the hydroxyl group of EPMO was substituted with PEG, the reaction was continued by the nucleophilic attack of the oxetane oxygen atom of EPMO. As a result, some new branches with one PEG chain on each branch were generated.
To understand how EPMO affects the resultant polymers, the mass ratio of EHMO to EPMO in polymerization was varied from 98:2 to 17:83. The resulting hyperbranched polyether polyols were found to have a range of properties and structural characteristics including molecular weight, DB, and glass transition temperature. The PEGylated carrier became more cytocompatible and water soluble as more EPMO was included. Our studies confirmed that incorporation of PEG into EHMO prior to polymerization limited PEGylation to a small portion of the branches, while at the same time enabling improvement of the cytocompatibility for the carrier. Mechanistic understanding of polymerization with the participation of PEGylated monomer will be sought in future studies for improved nanoscale and microscale control of such structures. In addition, the multiple hydroxyl end groups in P(EHMO-EPMO) could be utilized for covalently coupling drugs or other functional moieties of interest. Our future studies will include optimization and biofunctionalization of P(EHMO-EPMO) for efficient drug delivery.
Conclusion
A series of core-shell amphiphilic hyperbranched P(EHMO-EPMO) polymers were prepared via a one-pot sequential cationic ring-opening copolymerization of EHMO and its PEGylated derivative. The structure characteristics and properties of the hyperbranched copolyoxetanes, such as DB, molecular weight, and glass transition temperature were varied by changing the mass ratio of EHMO to EPMO. P(EHMO-EPMO) polymers became more cytocompatible with the increase in the percentage of EPMO. Particles for delivery of CPT were formulated from core-shell, hyperbranched P(EHMO-EPMO) copolyoxetanes, and the anticancer drug CPT using the single o/w solvent evaporation method. Sustained in vitro release of CPT was achieved for nine days. The encapsulated CPT exerted antitumor activity upon release from P(EHMO-EPMO) particles. In summary, hyperbranched P(EHMO-EPMO) can be engineered to possess biologically favorable properties and formulated for delivery of water-insoluble anticancer drugs.
